UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine

Bioorganic & medicinal chemistry letters, 2016-07, Vol.26 (13), p.3202-3206

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)

Bioorganic & medicinal chemistry letters, 2018-02, Vol.28 (3), p.541-546

2018

Link zum Volltext

Verfügbarkeit prüfen

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability

Bioorganic & medicinal chemistry letters, 2004-12, Vol.14 (24), p.6017-6021

2004

Link zum Volltext

Verfügbarkeit prüfen

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Bioorganic & medicinal chemistry letters, 2004-07, Vol.14 (14), p.3793-3797

2004

Link zum Volltext

Verfügbarkeit prüfen

Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor: efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF)

Bioorganic & medicinal chemistry letters, 2004-01, Vol.14 (2), p.535-539

2004

Link zum Volltext

Verfügbarkeit prüfen

Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late I Na i) of the cardiac Na v 1.5 channel with improved efficacy and potency relative to ranolazine

Bioorganic & medicinal chemistry letters, 2016-07, Vol.26 (13), p.3207-3211

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late I Na i) of the cardiac Na V 1.5 channel with improved efficacy and potency relative to ranolazine

Bioorganic & medicinal chemistry letters, 2016-07, Vol.26 (13), p.3202-3206

2016

Link zum Volltext

Verfügbarkeit prüfen

Using Patchxpress to Screen Blockers of the Cardiac Sodium Channel (Nav1.5) for Effects on Late INA, Peak INA, and Channel Kinetics

Biophysical journal, 2010-01, Vol.98 (3), p.113a-113a

2010

Link zum Volltext

Verfügbarkeit prüfen

Affinity and intrinsic efficacy (IE) of 5′-carbamoyl adenosine analogues for the A 1 adenosine receptor—efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF)

Bioorganic & medicinal chemistry letters, 2004, Vol.14 (2), p.535-539

2004

Link zum Volltext

Verfügbarkeit prüfen

Structure–affinity relationships of 5 ′ -aromatic ethers and 5 ′ -aromatic sulfides as partial A 1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Bioorganic & medicinal chemistry letters, 2004-07, Vol.14 (14), p.3793-3797

2004

Link zum Volltext

Verfügbarkeit prüfen

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi

Bioorganic & medicinal chemistry letters, 2019-08, Vol.29 (16), p.2428-2436

2019

Link zum Volltext

Verfügbarkeit prüfen

Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency

Bioorganic & medicinal chemistry letters, 2016-12, Vol.26 (24), p.5926-5930

2016

Link zum Volltext

Verfügbarkeit prüfen

Selective, high affinity A(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Bioorganic & medicinal chemistry letters, 2008-02, Vol.18 (4), p.1397-1401

2008

Link zum Volltext

Verfügbarkeit prüfen

The discovery of a selective, high affinity A(2B) adenosine receptor antagonist for the potential treatment of asthma

Bioorganic & medicinal chemistry letters, 2005-02, Vol.15 (3), p.609-612

2005

Link zum Volltext

Verfügbarkeit prüfen

Selective, high affinity A2B adenosine receptor antagonists : N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Bioorganic & medicinal chemistry letters, 2008-02, Vol.18 (4), p.1397-1401

2008

Link zum Volltext

Verfügbarkeit prüfen

Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors

Bioorganic & medicinal chemistry letters, 2009-04, Vol.19 (7), p.2048-2052

2009

Link zum Volltext

Verfügbarkeit prüfen

Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors

Bioorganic & medicinal chemistry letters, 2009-06, Vol.19 (11), p.3050-3053

2009

Link zum Volltext

Verfügbarkeit prüfen

The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma

Bioorganic & medicinal chemistry letters, 2005-02, Vol.15 (3), p.609-612

2005

Link zum Volltext

Verfügbarkeit prüfen

Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors

Bioorganic & medicinal chemistry letters, 2009-08, Vol.19 (15), p.4070-4074

2009

Link zum Volltext

Verfügbarkeit prüfen

Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists

Bioorganic & medicinal chemistry letters, 2006-01, Vol.16 (2), p.302-306

2006

Link zum Volltext

Verfügbarkeit prüfen

Enzymatic Targets in the Triglyceride Synthesis Pathway

Annual Reports in Medicinal Chemistry, 2010, Vol.45, p.109-122

2010

Link zum Volltext

Verfügbarkeit prüfen

Selective, high affinity A sub(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Bioorganic & medicinal chemistry, 2008-02, Vol.18 (4), p.1397-1401

2008

Link zum Volltext

Verfügbarkeit prüfen

Selective, high affinity A 2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Bioorganic & medicinal chemistry letters, 2008, Vol.18 (4), p.1397-1401

2008

Link zum Volltext

Verfügbarkeit prüfen

Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors

Bioorganic & medicinal chemistry letters, 2009, Vol.19 (11), p.3050-3053

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(31)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine

Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor: efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF)

Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late I Na i) of the cardiac Na v 1.5 channel with improved efficacy and potency relative to ranolazine

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late I Na i) of the cardiac Na V 1.5 channel with improved efficacy and potency relative to ranolazine

Using Patchxpress to Screen Blockers of the Cardiac Sodium Channel (Nav1.5) for Effects on Late INA, Peak INA, and Channel Kinetics

Affinity and intrinsic efficacy (IE) of 5′-carbamoyl adenosine analogues for the A 1 adenosine receptor—efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF)

Structure–affinity relationships of 5 ′ -aromatic ethers and 5 ′ -aromatic sulfides as partial A 1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi

Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor

Selective, high affinity A(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

The discovery of a selective, high affinity A(2B) adenosine receptor antagonist for the potential treatment of asthma

Selective, high affinity A2B adenosine receptor antagonists : N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors

Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors

The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma

Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors

Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists

Enzymatic Targets in the Triglyceride Synthesis Pathway

Selective, high affinity A sub(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Selective, high affinity A 2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors

Aktive Filter

Suchergebnisse filtern